Second Haplo-transplantation for Graft Failure

NCT06512519 · tracked via the Priya Life Science China tracker

Sponsor

Peking University People's Hospital

Phase

Not applicable

Started

2024-07-01

Last updated

2024-11-07

Condition(s) studied

Graft FailureStem Cell Transplant Complications

Investigational drug(s) / intervention(s)

second allogeneic stem cell transplantation

second allogeneic stem cell transplantation: 1. Change another donor if possible 2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 ), cyclophosphamide (1g/m2/day, days -5 to -4) 3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)

Study summary

Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. There are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). However, the study was performed in single-center and with very small sample size. Therefore, it should be further validated via multicenter study. In this multi-center study, we aim to further evaluate the safety and efficacy of this protocol.

Eligibility

Sex

ALL

Min age

14 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * 1\. Primary disease: hematological malignancies (AML, CML, MDS, lymphoma, etc.); 2. Graft failure after the first haploidentical stem cell transplantation; 3. Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years. Exclusion Criteria: * 1\. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\<50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\>2; 5. Expected life time\<30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,

Primary outcome measure(s)

Engraftment of neutrophils — 28 days after second transplantation
Engraftment of neutrophils was defined as the first of 3 consecutive days when the absolute neutrophil count achieved 500/uL.

Trial sites (1)

Facility	City	Region	Status
Peking University People's Hospital	Beijing	Beijing Municipality	Recruiting

More Peking University People's Hospital trials in China

Longitudinal Cohort of Thrombosis and Hemostasis Diseases Recruiting

Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT Recruiting

Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging Recruiting

Critical Illness After Hematopoietic Cell Transplantation Starting soon

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma Recruiting

Other trials for the same condition

Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) Recruiting

Pilot Trial of Colchicine for Graft Failure in CABG Active, not recruiting

ATG Individualized Dosing Model in URD-PBSCT. Recruiting

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) Recruiting

Modified Second Haplo-transplantation for Graft Failure Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06512519 on ClinicalTrials.gov ↗ ← All trials in China